Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM9BQTX)

Drug Name
PIK-75 Drug Info
Synonyms PIK75; PIK 75; imidazopyridine derivative 8c [PMID 17601739]
Cross-matching ID
PubChem CID
10275789
ChEBI ID
CHEMBL94827
CAS Number
CAS 945619-31-8
TTD Drug ID
D00HSJ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Lysosome 2.37 0.00e+0 115/128 (89.84%) ATP6AP1;AP3S1;CTSC;...
ECM-receptor interaction 2.30 0.00e+0 80/88 (90.91%) AGRN;COL1A2;LAMB2;...
Complement and coagulation cascades 2.17 0.00e+0 76/85 (89.41%) F2R;SERPING1;PLAT;...
Fatty acid elongation 2.10 0.00e+0 19/27 (70.37%) HACD2;ACOT7;PPT1;...
Valine, leucine and isoleucine degradation 2.08 0.00e+0 42/48 (87.5%) ACADM;OXCT1;ALDH7A1;...
Phagosome 2.06 0.00e+0 118/152 (77.63%) HLA-DQA1;ATP6AP1;THBS2;...
Pentose phosphate pathway 2.00 0.00e+0 25/30 (83.33%) RPIA;TKTL1;ALDOA;...
Alanine, aspartate and glutamate metabolism 1.97 1.81e-3 27/37 (72.97%) ALDH5A1;GLUD2;GLUD1;...
Other glycan degradation 1.97 1.61e-3 13/18 (72.22%) MAN2C1;MAN2B2;MAN2B1;...
Oxidative phosphorylation 1.95 4.34e-3 93/133 (69.92%) ATP6AP1;TCIRG1;NDUFS7;...
One carbon pool by folate 1.93 5.26e-3 15/20 (75%) SHMT2;MTR;DHFR;...
Retrograde endocannabinoid signaling 1.93 4.82e-3 118/148 (79.73%) ADCY7;GNG10;ITPR3;...
Rheumatoid arthritis 1.91 4.45e-3 78/93 (83.87%) HLA-DQA1;ATP6AP1;CXCL5;...
Protein digestion and absorption 1.86 6.20e-3 78/103 (75.73%) COL3A1;COL5A2;COL1A2;...
Various types of N-glycan biosynthesis 1.84 6.75e-3 26/39 (66.67%) DDOST;DAD1;STT3A;...
Glycosaminoglycan degradation 1.84 6.33e-3 19/19 (100%) IDS;HEXA;GALNS;...
Propanoate metabolism 1.84 5.95e-3 30/34 (88.24%) ACAT1;SUCLG2;ECHS1;...
Renin-angiotensin system 1.84 5.62e-3 20/23 (86.96%) ATP6AP2;PRCP;CTSA;...
D-Glutamine and D-glutamate metabolism 1.83 5.33e-3 5/5 (100%) GLUD2;GLUD1;GLS;...
Type I diabetes mellitus 1.80 6.51e-3 38/43 (88.37%) HLA-DQA1;HLA-DPB1;CPE;...
Asthma 1.80 6.20e-3 25/31 (80.65%) HLA-DQA1;HLA-DPB1;PRG2;...
Butanoate metabolism 1.78 7.89e-3 23/28 (82.14%) ALDH5A1;OXCT1;ACAT1;...
Cell adhesion molecules 1.76 8.17e-3 118/148 (79.73%) ALCAM;HLA-DQA1;SDC2;...
Focal adhesion 1.75 1.08e-2 180/201 (89.55%) COL1A2;LAMB2;THBS2;...
Biosynthesis of unsaturated fatty acids 1.75 1.04e-2 21/27 (77.78%) HACD2;SCP2;ACOT7;...
Neutrophil extracellular trap formation 1.72 1.45e-2 101/189 (53.44%) CYBA;C3;CYBB;...
Glycolysis / Gluconeogenesis 1.71 1.50e-2 56/67 (83.58%) PCK1;ALDH7A1;ADH1B;...
Glycine, serine and threonine metabolism 1.70 1.86e-2 31/40 (77.5%) ALDH7A1;SHMT2;MAOA;...
Starch and sucrose metabolism 1.66 2.44e-2 25/36 (69.44%) GAA;HK3;MGAM;...
Fatty acid degradation 1.65 2.43e-2 40/43 (93.02%) ACADM;ALDH7A1;ACAT1;...
MicroRNAs in cancer -1.84 1.43e-2 146/310 (47.1%) CCNE2;SPRY2;VEGFA;...
Cell cycle -1.90 1.43e-2 110/124 (88.71%) CCNE2;GSK3B;CDC25C;...
mRNA surveillance pathway -1.95 9.54e-3 71/98 (72.45%) ACIN1;CPSF4;RNGTT;...
Ribosome biogenesis in eukaryotes -2.17 0.00e+0 52/108 (48.15%) NVL;NOP10;RAN;...
Spliceosome -2.19 0.00e+0 101/150 (67.33%) PRPF3;CTNNBL1;SRSF6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 0.08uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 0.08uM 6H
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 0.08uM 6H
MDST8 CVCL_1400 Homo sapiens 0.08uM 6H
NCI-H508 CVCL_1561 Homo sapiens 0.08uM 6H
SNU-1040 CVCL_5001 Homo sapiens 0.08uM 6H
SNU-C4 CVCL_5008 Homo sapiens 0.08uM 6H
SW480 CVCL_0546 Homo sapiens 0.08uM 6H
SW620 CVCL_0547 Homo sapiens 0.08uM 6H
SW948 CVCL_0550 Homo sapiens 0.08uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 0.08uM 6H
HT115 CVCL_1294 Homo sapiens 0.08uM 6H
RKO CVCL_0504 Homo sapiens 0.08uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.08uM 6H
SNG-M CVCL_1707 Homo sapiens 0.08uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 0.08uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.08uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 0.08uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 0.08uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 0.08uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 0.08uM 6H
T3M-10 CVCL_1729 Homo sapiens 0.08uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 0.08uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 0.08uM 6H
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 0.08uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 0.08uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 0.08uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 0.08uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 0.08uM 6H
OV7 CVCL_1623 Homo sapiens 0.08uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 0.08uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 0.08uM 6H
RMUG-S CVCL_1666 Homo sapiens 0.08uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 0.08uM 6H
Peripheral blood
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 0.08uM 6H
PL-21 CVCL_2161 Homo sapiens 0.08uM 6H
SKM-1 CVCL_0010 Homo sapiens 0.08uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.08uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.08uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 0.08uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 0.08uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.08uM 6H